Stockreport

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

ProMIS Neurosciences Inc.  (PMN) 
PDF Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical [Read more]